Showing 6831-6840 of 8861 results for "".
- Study: Sleeping It Off Is No Wrinkle Curehttps://practicaldermatology.com/news/study-sleeping-it-off-is-no-wrinkle-cure/2458486/Stomach and side sleeping positions cause wrinkles over time, and the effect is worsened with advancing age, new research suggests. The findings are published in Aesthetic Surgery Journal.<
- Take That, Acne: BPX-01 Topical Gel Delivers Minocycline Precisely to the Skinhttps://practicaldermatology.com/news/take-that-acne-bpx-01-topical-gel-delivers-minocycline-precisely-to-the-skin/2458490/BioPharmX Corporation’s novel topical minocycline, BPX-01, may be as effective as its oral counterpart minus the systemic side effects, new research suggests. "These results are promising, that topical minocycline gel delivered as BP
- Novan: First Patient Dosed in Phase 2 Anti-Fungal Programhttps://practicaldermatology.com/news/nolan-first-patient-dosed-in-phase-2-anti-fungal-program/2458492/The first patient has been dosed in Novan's clinical program to evaluate the efficacy and safety of topical nitric oxide product candidate SB208 in the treatment of infections caused by dermatophytes such as Trichophyton rubrum (“T. rubrum”). Novan is developing
- Clearpath Derm Introduces New Digital Pathology Servicehttps://practicaldermatology.com/news/clear-path-derm-introduces-new-digital-pathology-service/2458560/Clearpath Derm has launched Clearpath 3.0, a digital software solution for dermatopathology. Clearpath 3.0 provides dermatologists with real-time access to whole slide images and patient case information from anywhere using a tablet, iPad or computer.
- Galderma Unveils the New Cetaphil Brand Graphics & Packaginghttps://practicaldermatology.com/news/galderma-unveils-the-new-cetaphil-brand-graphics-packaging/2458590/Galderma Laboratories, L.P., redesigned the graphics and packaging of its Cetaphil product line to provide a more simplified shopping experience at shelf, improved portfolio differentiation, as well as clarity of product benefits. "The packaging
- Kourtney Kardashian is Manuka Doctor's New Brand Ambassadorhttps://practicaldermatology.com/news/kourtney-kardashian-is-manuka-doctors-new-brand-ambassador/2458614/Kybella has Khloe, and now Manuka Doctors got Kourtney. Kourtney Kardashian is the new face of Manuka Doctor, a skincare line comprising Manuka Honey and patented Purified Bee Venom.
- Let the Sun Shine In? Research Reveals Why Sunbathers May Live Longer than Sun Avoidershttps://practicaldermatology.com/news/let-the-sun-shine-in-research-reveals-why-sunbathers-may-live-longer-than-sun-avoiders/2458634/Sunbathers tend to live longer than their shade-seeking counterparts despite their increased risk for skin cancer, but why? New research suggests that a decrease in heart disease and noncancer/non-heart disease deaths may explain the paradox.
- New System Depicts Skin Regeneration in Technicolorhttps://practicaldermatology.com/news/new-system-depicts-skin-regeneration-in-technicolor/2458638/Thanks to a genetically engineered line of technicolor zebrafish, researchers can now visualize skin regeneration at high resolution in real time. Many available methods rely on samples that are "snapshots" of cell growth and movement, but the new system, called Skinbow, c
- Cipher Pharmaceuticals Appoints New President and General Manager of US Businesshttps://practicaldermatology.com/news/cipher-pharmaceuticals-appoints-new-president-and-general-manager-of-us-business/2458662/Cipher Pharmaceuticals Inc. named Ralph Bohrer as President and General Manager of its US subsidiary. Mr. Bohrer is a seasoned pharmaceutical executive with 30 years of experience in sales and marketing leadership for growing dermatology companies. Prior to
- Valeant Pharmaceuticals Announces Management And Business Updatehttps://practicaldermatology.com/news/valeant-pharmaceuticals-announces-management-and-business-update/2458677/J. Michael Pearson has returned as Valeant Pharmaceuticals International, Inc.’s chief executive officer following his recovery from severe pneumonia and other complications. Howard B. Schiller, Valeant's interim chief executive officer, will transition out of his current duties but wil